Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Irinotecan + YIV-906|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|YIV-906||PHY906|KD018||YIV-906 (KD018) is an herbal formulation whose mechanism of action is unclear, but which results in inhibition of CYP3A4, MMP, NF-KB, beta-glucuronidase, and the NK-1 receptor, as well as modulation of certain cytokines, macrophages and lymphocytes (PMID: 25819872, PMID: 31617551).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|